WASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular...
Hence then, the article about vanda pharmaceuticals announces fda acceptance of biologics license application filing for imsidolimab for the treatment of generalized pustular psoriasis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis )
Also on site :
- Amanda Schull and Victor Webster Play Matchmaker in Hallmark’s ‘’Tis the Season for Setups’—Exclusive Sneak Peek
- 1966 Hit, Featured in Many Movies, Was About Working in the Coal Mines Even Though the Singer Had Never Actually Been in One
- Julia Stiles to Honor Late Co-Star Heath Ledger in Heartwrenching ‘Dancing with the Stars’ Dedication Night